News
Pyoderma gangrenosum: Understanding the difficult diagnosis
Ulcerative disorder can be mistaken for other conditions, dermatologist says.
News
Medication in heart failure: Pro tips on therapy with the ‘four pillars of survival’
Consider multiple factors when titrating various medications.
News
In-hospital resuscitation: Focus on effective chest pumps, prompt shocks
Consider mechanical piston compressions and even “reverse CPR” when appropriate.
News
Garbage out: How much trash does a Mohs surgery practice produce?
Small clinic estimates that it produces a ton of noncontaminated surgical waste each year.
News
Survey: Many Mohs surgeons are struggling on the job
More than half of female respondents were ‘at risk,’ per assessment.
News
Lower SARS-CoV-2 vaccine responses seen in patients with immune-mediated inflammatory diseases
Patients who take methotrexate or rituximab seem to be especially vulnerable.
News
Telemedicine is popular among Mohs surgeons – for now
Almost all of those surveyed have used it during pandemic, but fewer want to keep it around.
News
What to know about COVID-19 vaccines and skin reactions
These manifestations can appear several days after an injection but tend not to be serious.
News
NSAIDs don’t make COVID-19 worse in hospitalized patients
In a British study, hospitalized patients didn’t fare worse if they’d taken NSAIDs regularly before admission.
News
Genital skin exams in girls: Conduct with care, look for signs of abuse
Dermatologist offers advice about putting children and parents at ease.
News
LGBTQ patients face unique skin risks
Watch out for skin cancer in gay men, hormone-induced acne in transmasculine patients
News
Psoriasis associated with an increased risk of COVID-19 in real-world study
Those treated with TNF-alpha inhibitors, methotrexate, and apremilast had statistically lower risks of COVID-19 vs. those on topical therapy.
News
Tofacitinib: Small study shows big cutaneous sarcoidosis response
“Not only did patients get better, but they were in many cases able to come off their baseline immunosuppressive regimen."
News
S1P-receptor modulator shows promise in phase 2b AD trial
Experimental medication appears to prevent immune cells from entering the skin, study presenter says.